NVAX Stock Analysis: Buy, Sell, or Hold?
NVAX - Novavax Inc
$8.88
0.32 (3.74%)
▲
5d:
-2.74%
30d:
-19.93%
90d:
-0.78%
BUY
HIGH Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Distribution
None View Scanner →
Strength: 10.0/10
Get Alerted When NVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NVAX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: NVAX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: NVAX is currently trading at $8.88, which is considered slightly low relative to its 30-day fair value range of $8.69 to $10.16. From a valuation perspective, the stock is trading at a discount (Forward PE: -34.9) compared to its historical average (35.1). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, NVAX is in a uptrend. Immediate support is located at $8.27, while resistance sits at $9.99. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.11 (+58.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVAX is in a uptrend. Immediate support is located at $8.27, while resistance sits at $9.99. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.11 (+58.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$8.69 -
$10.16
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 58.9% below Wall St target ($14.11)
Trading Range Analysis
30-Day Trading Range
$8.69 -
$10.16
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$8.27
Resistance Level
$9.99
Current Trend
Uptrend
Technical data as of
Jun 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-34.89
Wall Street Target
$14.11
(+58.9%)
Revenue Growth (YoY)
-79.1%
Earnings Growth (YoY)
-38.1%
Profit Margin
-14.7%
PE vs Historical
-34.9 vs 35.1
CHEAP
Share & Embed Analysis
Last updated: June 28, 2026 9:27 PM ET
Data refreshes hourly during market hours. Next update: 10:27 PM
Data refreshes hourly during market hours. Next update: 10:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 67 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
Advanced NVAX Option Strategies
Professional options setups generated by AI based on today's NVAX price and gamma walls.
